DEERFIELD, Ill -- Lundbeck Inc. today announced the presentation of results from an open-label extension study of Xenazine® (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HDData from this study demonstrated that after an 80-week treatment period, subjects tre

read more>>

The National Ataxia Foundation (NAF), in conjunction with the University of Chicago program in pathobiology and translational neuroscience, will hold its third annual Ataxia Investigators Meeting March 9-11, 2010, at the Hyatt Regency O'Hare, in Rosemont, IllA three-day meeting for patients, careg

read more>>

CARLSBAD, Calif. -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it has initiated a Phase 1 study of ISIS-SOD1Rx in patients with an inherited, aggressive form of Lou Gehrig's disease also known as familial amyotrophic lateral sclerosis (ALSApproximately 20 percent of all familia

read more>>

CAMBRIDGE, Mass. -- Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,655,221 (the '221 patent) which protects the target product profile for its PI-2301 peptide copolymer for the treatment of multiple sclerosis, and other autoimmune diseasesT

read more>>

In final draft guidance published today (4 March) NICE has recommended infliximab and adalimumab as treatment options for people with severe, active Crohn’s disease whose condition has not responded to conventional therapy, or who are intolerant of or have contraindications to conventional C

read more>>

The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemiaThis draft is now with consultees who have the opp

read more>>

King of Prussia, PA -- CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Hizentra™, Immune Globulin Subcutaneous (Human), 20% Liquid, for treating patients diagnosed with primary immunodeficiency (PIA once weekly immunoglobulin (I

read more>>

ISLAMABAD -- The Ministry of Health has decided to send blood samples of seven children suffering from a rather uncommon disorder to Saint John’s Dermatology Centre in London for tests, because the country does not have facilities for diagnosing certain skin diseasesThe children from Balochi

read more>>

Islamabad -- The Pakistan Medical Research Council (PMRC) has launched the world’s first comprehensive snakebite protocol called 'A2 Snakebite Management in Asia and Africa' for use by doctors to treat snakebite in the key areas of Asia and AfricaSnakebite has been described as a 'neglected

read more>>

SOUTH PLAINFIELD, N.J. & CAMBRIDGE, Mass. -- PTC Therapeutics, Inc. and Genzyme Corporation (Nasdaq: GENZ) today announced preliminary results from the Phase 2b clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation Duchenne/Becker Muscular Dystrophy (nmDBMD

read more>>